zerlasiran

From Aaushi
Jump to navigation Jump to search
[1]

Indications

  • a long-acting agent directed at lowering Lp(a) levels*

* 90% reduction in serum Lp(a) levels in phase 2 trial

More general terms

References

  1. ↑ Hughes S Phase 2 Results: Zerlasiran siRNA Drug Lowers Lp(a) by 90% Cardiology News. March 18, 2024 https://www.mdedge.com/cardiology/article/268324/lipid-disorders/phase-2-results-zerlasiran-sirna-drug-lowers-lpa-90 https://www.medscape.com/viewarticle/zerlasiran-sirna-drug-lowers-lp-90-phase-2-results-2024a10004s8
Retrieved from "https://aaushi.info/w/index.php?title=A58612&oldid=1207561"